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et al.: Process for the preparation of Isoproternol hydrochloride

Process for the preparation of Isoproternol Hydrochloride
3,4-Dihydroxy-α-[(isopropylamino)methyl] benzyl alcohol hydrochloride is also
known as Isoproterenol hydrochloride compound of formula-1a.

Formula-1a
Isoproterenol hydrochloride is approved by USFDA for medication used for mild
or transient episodes of heart block that do not require electric shock or pacemaker
therapy, for serious episodes of heart block and Adams-Stokes attacks (except when
caused by ventricular tachycardia or fibrillation), for use in cardiac arrest until electric
shock or pacemaker therapy, the treatments of choice, is available, for bronchospasm
occurring during anesthesia and As an adjunct to fluid and electrolyte replacement therapy
and the use of other drugs and procedures in the treatment of hypovolemic and septic
shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic
shock.
Isoproterenol sulphate and its process for the preparation disclosed in US2308232.
However, this patent is silent on the preparation of Isoproterenol hydrochloride.
Various

other

patent

documents

IN2529/CHE/2015,

IN201621010158,

IN201721000708 and IN201841022861 disclose the process for the preparation of
Isoproterenol hydrochloride.

The first embodiment of the present publication provides a process for preparation
of Isoproterenol hydrochloride of formula-1a comprising:
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a)

reacting

2-chloro-1-(3,4-dihydroxyphenyl)ethanone

of

formula-2

with

isopropylamine in absence of solvent and followed by treating with hydrochloric acid
in

solvent

to

provide

1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanone

hydrochloride of formula-3,
b) hydrogenating

the

1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanone

hydrochloride of formula-3 with palladium on charcoal in a solvent to provide
Isoproterenol hydrochloride of formula-1a.
Hydrochloric acid used in step-a) is concentrated hydrochloric acid or
isopropanolic hydrochloric acid.
The reaction in step-a) is carried out in absence of solvent.
Second embodiment of the present publication provides a process for the
purification of Isoproterenol hydrochloride of formula-1a comprising:
a) slurrying the crude isoproterenol hydrochloride in ester solvent or alcohol,
b) optionally recrystallizing the compound obtained in step-a) in alcohol solvent to
get pure isoproterenol hydrochloride.
wherein ester solvent in step-a) is selected from methyl acetate, ethyl acetate, n-propyl
acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, tert-butyl acetate and mixtures
thereof; alcohol solvent in step-a) and step-b) is selected from methanol, ethanol, npropanol, isopropanol, n-butanol, iso-butanol, 2-butanol, tert-butanol and mixtures
thereof.
Isoproterenol hydrochloride prepared according to the present invention can be
further micronized or milled in conventional techniques to get the desired particle size to
achieve desired solubility profile based on different forms of pharmaceutical composition
requirements. Techniques that may be used for particle size reduction include, but not
limited to ball milling, roll milling and hammer milling, and jet milling. Milling or
micronization may be performed before drying, or after the completion of drying of the
product.
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In an embodiment of the present invention provides a pharmaceutical composition
comprising Isoproterenol hydrochloride and one or more pharmaceutically acceptable
excipient. As used herein, the term "pharmaceutical compositions" or "pharmaceutical
formulations" include tablets, pills, powders, liquids, suspensions, emulsions, granules,
capsules, suppositories, or injection preparations.
The process described in the present publication was demonstrated in examples
illustrated below. These examples are provided as illustration only and therefore should
not be construed as limitation of the scope of the invention.
Examples:
Example-1: Preparation of 2-chloro-1-(3,4-dihydroxyphenyl)ethanone of formula-2
Catechol (100 g) was lot wise added to pre-cooled mixture of aluminum chloride (300 g)
and dichloromethane (1000 ml) at 0-10°C and stirred at the same temperature.
Chloroacetyl chloride (76 ml) in dichloromethane (200 ml) was slowly added to reaction
mixture at 0-10°C and stirred. Raised the temperature to 25-30°C and stirred at the same
temperature. The reaction mixture was quenched into mixture of ice water and
hydrochloric acid mixture at 10-20°C and stirred at the same temperature. Filtered the
solid and washed with water. The obtained solid was recrystallized from water and dried
to get the title compound.
Yield: 131 g
Example-2: Preparation of 1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanone
hydrochloride of formula-3
2-chloro-1-(3,4-dihydroxyphenyl)ethanone of formula-2 (100 g) was added in lot wise to
isopropylamine (1000 ml) at 25-30°C and stirred at the same temperature. Distilled off the
solvent completely from reaction mixture and co-distilled with acetone. Acetone (1000
ml) added to obtained compound at 35-40°C and stirred at the same temperature. Cooled
the reaction mixture to 25-30°C and acidified with isopropanolic hydrochloric acid (300
ml) and stirred at the same temperature. Filtered the solid, washed with acetone and dried
to get the title compound.
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Yield: 100.5 g.

Example-3: Preparation of Isoproterenol hydrochloride of formula-1a
Carbon treatment was given to the 2-chloro-l-(3,4-dihydroxyphenyl)ethanone hydrochloride of
formula-3 (50 g) in the mixture of methanol and water. The obtained filtrate was transferred to
autoclave and 5% Pd/C (10 g) added to it. Applied hydrogen pressure to the reaction mixture at
25-35°C. Filtered the mixture through hyflow bed and washed with methanol. Carbon treatment
was given the obtained filtrate. Distilled off the solvent form the filtrate and co-distilled with
isopropanol.

Example-4: Purification of Isoproterenol hydrochloride of formula-1a
Crude Isopreterenol hydrochloride is slurried in ethyl acetate for 3 times at 25-30°C and further
recrystallized the obtained compound in ethanol to get the pure Isoproterenol hydrochloride.
Yield: 22 g; purity by HPLC: 99.83%.

*******
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